278 related articles for article (PubMed ID: 22616642)
1. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Steegmann JL; Cervantes F; le Coutre P; Porkka K; Saglio G
Leuk Lymphoma; 2012 Dec; 53(12):2351-61. PubMed ID: 22616642
[TBL] [Abstract][Full Text] [Related]
2. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Jabbour E; Kantarjian H; Cortes J
Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
[TBL] [Abstract][Full Text] [Related]
4. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
5. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Quintás-Cardama A; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
7. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Jabbour E; Deininger M; Hochhaus A
Leukemia; 2011 Feb; 25(2):201-10. PubMed ID: 20861918
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
9. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Holstein SA; Stokes JB; Hohl RJ
Leuk Res; 2009 Feb; 33(2):344-7. PubMed ID: 18835038
[TBL] [Abstract][Full Text] [Related]
10. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
11. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
12. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
15. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
16. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Deadman BJ; Hopkin MD; Baxendale IR; Ley SV
Org Biomol Chem; 2013 Mar; 11(11):1766-800. PubMed ID: 23247657
[TBL] [Abstract][Full Text] [Related]
17. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Hantschel O; Rix U; Superti-Furga G
Leuk Lymphoma; 2008 Apr; 49(4):615-9. PubMed ID: 18398720
[TBL] [Abstract][Full Text] [Related]
18. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Radich JP
Cancer; 2012 Jan; 118(2):300-11. PubMed ID: 21717440
[TBL] [Abstract][Full Text] [Related]
19. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL
N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]